The 44th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 47th Survey in 2021)].
Subcommittee for Safety Issues of Radiopharmaceuticals, Medical Science and Pharmaceutical Committee, Japan Radioisotope Association, Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura
Kaku igaku. The Japanese journal of nuclear medicine 2023This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2021 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 970 institutions out of 1,194 to which the questionnaire had been sent. A total of 928,921 radiopharmaceutical administrations were reported. Twelve cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.3. Three cases of defective products were reported. The incidence of defective products per 100,000 cases was 0.3.
Citation
Subcommittee for Safety Issues of Radiopharmaceuticals, Medical Science and Pharmaceutical Committee, Japan Radioisotope Association, Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura. The 44th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 47th Survey in 2021)]. Kaku igaku. The Japanese journal of nuclear medicine. 2023;60(1):1-12
Mesh Tags
Substances
PMID: 36792223
View Full Text
